Biomarkers Identification for Diagnosis and Treatment of SARS-COV-2 Infection
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coronavirus
- Sponsor
- University of Catanzaro
- Enrollment
- 110
- Locations
- 1
- Primary Endpoint
- Biomarkers expression
- Last Updated
- 4 years ago
Overview
Brief Summary
Acute lung injury represents the most severe form of the viral infection sustained by coronavirus disease 2019 (Covid-19) also named as SARS-CoV-2, a new virus emerged in December 2019 in Wuhan (China). The diagnosis is clinical and patients develop flu-like syndrome with fever and cough; patients with clinical symptoms can perform a swab test, including molecular and/or antigen swab, for diagnosis of positivity to Covid-19. Even if diagnosis and treatment are well described, to date, this viral pandemic infection induces an increased mortality in the world. The aim of the present project is to evaluate specific biomarkers that could be used for patient stratification and for tailor therapy in COVID-19 infected patients.
Investigators
Luca Gallelli
Clinical Professor
University of Catanzaro
Eligibility Criteria
Inclusion Criteria
- •Aged between 18 and 75 years, extremes included, male or female In conscious patients, ability to understand and the willingness to sign a written informed consent document; in unconscious patients informed consent will be signed from parents or legal tutors.
Exclusion Criteria
- •Patients that don't sign the informed consent
Outcomes
Primary Outcomes
Biomarkers expression
Time Frame: up to 30 days
Change in biomarkers (microRNAs, oxidative stress, Neuron-Specific Enolase, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) in covid-19 positive patients vs covid-negative patients
Liver Biomarkers expression
Time Frame: up to 30 days
Change in CYP450 expression in covid-19 positive patients that develop adverse drug reactions or drug inefficacy
Secondary Outcomes
- biomarkers expression (microRNAs, oxidative stress, Neuron-Specific Enolase, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) after treatment(60 days)